Asparaginase erythrocyte encapsulated - ERYtech Pharma

Drug Profile

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase; GRASPA; L-asparaginase loaded erythrocytes

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ERYtech Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Pancreatic cancer
  • Preclinical Breast cancer; Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 27 Mar 2018 ERYtech enters into a service-based partnership agreement with Oncodesign Biotechnology for eryaspase Solid tumours
  • 12 Mar 2018 ERYtech Pharma expects CHMP feedback on MAA resubmission for asparaginase erythrocyte encapsulated in refractory and relapsed precursor cell lymphoblastic leukaemia (ALL) by the end of 2018
  • 12 Mar 2018 ERYtech Pharma plans a proof-of concept phase II trial for Pancreatic cancer (First-line treatment) by the end of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top